Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av BI-1206 i kombinasjon med rituximab hos personer med indolent B-celle non-Hodgkin lymfom

1. oktober 2026 oppdatert av: BioInvent International AB

Fase 1/2a klinisk utprøving av BI-1206, et monoklonalt antistoff mot CD32b (FcYRIIB), i kombinasjon med rituximab hos pasienter med indolent B-celle non-Hodgkin lymfom som har fått tilbakefall eller er refraktær mot rituximab

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Studieoversikt

Detaljert beskrivelse

This is a Phase 1/2a, multicenter, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab with or without acalabrutinib in subjects with indolent relapsed or refractory B-cell NHL, sub-types FL (except FL grade 3B), MZL, and MCL.

Phase 2a, consists of signal seeking cohorts followed by a randomized, parallel, two-arm dose optimization.

The trial consists of 2 main parts:

Phase 1

- Dose Escalation, with two different Arms assessing IV or SC dosing of BI-1206 in combination with rituximab, with dose escalation cohorts and selection of the IV and SC doses of BI-1206 for Phase 2a

Phase 2a

  • Dose Expansion, with one expansion cohort evaluating the selected IV dose of BI-1206 in combination with rituximab
  • Signal Seeking, assessing IV and SC dosing of BI-1206 in combination with rituximab and acalabrutinib. The Signal Seeking will consist of a Safety Run-in and an Expansion
  • Dose Optimization to select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib

Studietype

Intervensjonell

Registrering (Antatt)

140

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Curitiba, Brasil
        • Har ikke rekruttert ennå
        • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eduardo Munhoz, MD
      • Rio de Janeiro, Brasil
      • São Paulo, Brasil
      • São Paulo, Brasil
        • Har ikke rekruttert ennå
        • Hospital Sírio-Libanês
        • Hovedetterforsker:
          • Ana Rita Da Fonseca, MD
        • Ta kontakt med:
      • São Paulo, Brasil
        • Har ikke rekruttert ennå
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
        • Ta kontakt med:
        • Hovedetterforsker:
          • Juliana Pereira, MD
      • São Paulo, Brasil
      • São Paulo, Brasil
      • São Paulo, Brasil
        • Rekruttering
        • Hospital Israelita Albert Einstein
        • Hovedetterforsker:
          • Guilherme Perini, MD
        • Ta kontakt med:
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil
        • Rekruttering
        • Hospital São Rafael
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ana Luiza Schriefer, MD
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil
        • Rekruttering
        • Hospital de Clínicas de Porto Alegre
        • Hovedetterforsker:
          • Laura Maria Fogliatto, MD
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Aktiv, ikke rekrutterende
        • Emory University Hospital
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40207
        • Rekruttering
        • Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
        • Hovedetterforsker:
          • Don Stevens, MD
      • Grudziądz, Polen, 86-300
        • Avsluttet
        • Szpital Specjlistyczny
      • Krakow, Polen
        • Avsluttet
        • Małopolskie Centrum Medyczne
      • Barcelona, Spania
        • Rekruttering
        • Institut Català d'Oncologia, L'Hospitalet de Llobregat
        • Hovedetterforsker:
          • Eva Domingo Domenech, MD
        • Ta kontakt med:
      • Madrid, Spania
        • Rekruttering
        • University Hospital Fundacion Jimenez Diaz
        • Hovedetterforsker:
          • Raul Cordoba Mascunano, MD
        • Ta kontakt med:
    • Barcelona
      • Badalona, Barcelona, Spania
        • Rekruttering
        • Hospital ICO, Trias i Pujol
        • Hovedetterforsker:
          • Juan Manuel Sancho Cia, MA
        • Ta kontakt med:
      • Barcelona, Barcelona, Spania
        • Rekruttering
        • Hospital Universitari Vall d'Hebron
        • Hovedetterforsker:
          • Pablo Abrisqueta Costa, MD
        • Ta kontakt med:
      • Barcelona, Barcelona, Spania
        • Rekruttering
        • Hospital de la Santa Creu i Sant Pau, Dep Hematologia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sara Miqueleiz Alamos, MD
    • Madrid
      • Madrid, Madrid, Spania
        • Rekruttering
        • Hospital Universitario HM Sanchinarro
        • Ta kontakt med:
        • Hovedetterforsker:
          • Augustin Penedo Coello, MD
      • Madrid, Madrid, Spania
        • Rekruttering
        • Hospital General Universitario Gregorio Marañon-Oncología Médica
        • Hovedetterforsker:
          • Mariana Bastos Oreiro, MD
        • Ta kontakt med:
    • Murcia
      • Murcia, Murcia, Spania
        • Har ikke rekruttert ennå
        • Hospital Universitario Virgen de la Arrixaca
        • Hovedetterforsker:
          • Joaquin Gomez Espuch, MD
        • Ta kontakt med:
    • Seville
      • Seville, Seville, Spania
        • Rekruttering
        • Hospital University Virgen Macarene
        • Hovedetterforsker:
          • Sergio Ortegon Alcaide, MD
        • Ta kontakt med:
      • Lund, Sverige, SE-22185
        • Avsluttet
        • Department of Oncology, Skåne University Hospital
    • Sweden
      • Uppsala, Sweden, Sverige, 751 85
        • Avsluttet
        • Department of Oncology, Academical Hospital
      • Stuttgart, Tyskland
        • Tilbaketrukket
        • Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland
        • Har ikke rekruttert ennå
        • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
        • Hovedetterforsker:
          • Eckhart Weidmann, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Are ≥ 18 years of age by initiation of study treatment.
  2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)
  3. Have measurable nodal disease
  4. Are willing to undergo lymph node biopsies or biopsies of other involved tissue
  5. Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists
  6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen
  7. Have a life expectancy of at least 12 weeks
  8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  9. Have CD20+ malignancy
  10. Have hematological and biochemical indices within prespecified ranges

Exclusion Criteria:

  1. Have had an allogenic bone marrow or stem cell transplant within 12 months

  2. Have presence of active chronic graft versus host disease

  3. Have current leptomeningeal lymphoma or compromise of the central nervous system

  4. Have transformed lymphoma from a pre-existing indolent lymphoma

  5. Have Waldenstrom's Macroglobulinemia or FL grade 3B,

  6. Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.

  7. Have known or suspected hypersensitivity to rituximab or BI-1206

  8. Have cardiac or renal amyloid light-chain amyloidosis

  9. Have received any of the following:

    1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
    2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
    3. Immunotherapy within 8 weeks
    4. Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib
  10. Have ongoing toxic manifestations of previous treatments.

  11. Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).

  12. Have had major surgery from which the subject has not yet recovered.

  13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.

  14. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

  15. Have an active, known or suspected autoimmune disease.

  16. Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA])

  17. Have current malignancies of other types

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: BI-1206 IV Dose Escalation

Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Andre navn:
  • Ruxience
Eksperimentell: BI-1206 SC Dose Escalation

Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Andre navn:
  • Ruxience
Eksperimentell: Phase 2a IV Dose expansion

BI-1206 IV in Combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Andre navn:
  • Ruxience
Eksperimentell: Phase 2a SC Signal seeking

SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Andre navn:
  • Ruxience

Acalabrutinib 100 mg orally as per SmPC

Andre navn:
  • Calquence
Eksperimentell: Phase 2a IV Signal Seeking

IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Andre navn:
  • Ruxience

Acalabrutinib 100 mg orally as per SmPC

Andre navn:
  • Calquence

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab and/or acalabrutinib
Tidsramme: During the 28-day treatment period on induction therapy

Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab or rituximab and acalabrutinib in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), subtypes follicular lymphoma (FL)(except FL grade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Assessment will be done according to National Cancer Institute (NCI-CTCAE) criteria v. 5.0.

During the 28-day treatment period on induction therapy
Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)
Tidsramme: During the 28-day treatment period on induction therapy

Phase 1:

Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.

During the 28-day treatment period on induction therapy
Determine the recommended dose of BI-1206 in combination with rituximab and acalabrutinib
Tidsramme: During the 28-day treatment period on induction therapy

Phase 2a:

Select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib.

During the 28-day treatment period on induction therapy

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Evaluation of PK parameters for BI-1206
Tidsramme: Up to 1 year

PK parameters assessed will include AUC, Cmax, time to Cmax and t1/2 of BI-1206 when administered IV or SC

Up to 1 year
Evaluation of ADA (immunogenicity) response to BI-1206
Tidsramme: Up to 1 year

Assess the incidence and titre of antidrug antibodies of BI-1206 in serum when administered IV or SC in combination with rituximab or rituximab and acalabrutinib.

Up to 1 year
Measurement of peripheral blood B-lymphocytes depletion
Tidsramme: Up to 1 year

Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib measuring B Lymphocytes CD19+ (absolute value) as part of hematology assessment to determine the level of peripheral blood B lymphocyte depletion.

Up to 1 year
Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).
Tidsramme: Up to 1 year

Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.

Up to 1 year

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Expression levels of CD32b protein
Tidsramme: Up to 1 year

To investigate CD32b protein expression levels using flow cytometry to evaluate any potential correlation with clinical responses. Change from baseline expression levels will be summarized descriptively by dose cohort and/or response to treatment.

Up to 1 year
Assessment of Patient Reported Outcomes using the NCI PRO-CTCAE questionnaire
Tidsramme: Up to 1 year

The NCI PRO-CTCAE will be used to evaluate symptomatic toxicities reported by patients. The questionnaire characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities, all toxicities that can be meaningfully reported from the patient perspective.

Responses are scored from 0 to 4 (or 0/1 for absent/present). Scores for each attribute (frequency, severity and/or interference) will be presented descriptively (e.g. summary statistics or graphical presentations).

Up to 1 year
Expression levels of CD32b and/or other immunological markers
Tidsramme: Up to 1 year

Perform whole-transcriptome, quantitative polymerase chain reaction (qPCR) and/or IHC analysis of lymph node biopsies to evaluate potential correlation with clinical responses.

Up to 1 year
Measurement of serum cytokines levels and/or soluble CD32b.
Tidsramme: Up to 1 year

Study the potential cause of infusion related reactions (IRRs), such as cytokine release signs, C-reactive protein (CRP) and/or soluble CD32b.

Up to 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. mai 2018

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

30. september 2027

Datoer for studieregistrering

Først innsendt

17. mai 2018

Først innsendt som oppfylte QC-kriteriene

18. juni 2018

Først lagt ut (Faktiske)

27. juni 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.

IPD-delingstidsramme

Within one year from end of study

Tilgangskriterier for IPD-deling

Paper copy of CSR

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere